

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

**FORM 8-K**

CURRENT REPORT

Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934

Date of Report  
(Date of earliest event reported):

October 6, 2011

---

**THERMO FISHER SCIENTIFIC INC.**

(Exact name of Registrant as specified in its Charter)

Delaware (State or other jurisdiction of incorporation or organization)	1-8002 (Commission File Number)	04-2209186 (I.R.S. Employer Identification Number)
---	------------------------------------	--

81 Wyman Street Waltham, Massachusetts (Address of principal executive offices)	02451 (Zip Code)
---	---------------------

(781) 622-1000  
(Registrant's telephone  
number including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**THERMO FISHER SCIENTIFIC INC.**

**Item 2.02      Results of Operations and Financial Condition**

On October 6, 2011, the Registrant announced that it has established a new financial reporting segment, called Specialty Diagnostics. As a result of this change, Thermo Fisher Scientific's financial performance will be reported in three segments instead of two, effective with the company's third fiscal quarter of 2011. The company has included in the press release issued in connection with the announcement certain unaudited historical financial results reflecting the new segment reporting structure. The full text of the press release is attached as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.

The information contained in this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01    Financial Statements and Exhibits**

(d)   Exhibits

The following Exhibit relating to Item 2.02 shall be deemed "furnished", and not "filed":

99.1   Press Release dated October 6, 2011

**THERMO FISHER SCIENTIFIC INC.**

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized, on this 6th day of October, 2011.

**THERMO FISHER SCIENTIFIC INC.**

By: /s/ Peter E. Hornstra  
Peter E. Hornstra  
Vice President and Chief Accounting Officer

**FOR IMMEDIATE RELEASE**

Media Contact Information:  
Ron O'Brien  
Phone: 781-622-1242  
E-mail: ron.obrien@thermofisher.com  
Website: www.thermofisher.com

Investor Contact Information:  
Ken Apicerno  
Phone: 781-622-1294  
E-mail: ken.apicerno@thermofisher.com

**Thermo Fisher Scientific Establishes New Reporting Segment,  
Specialty Diagnostics**

WALTHAM, Mass. (October 6, 2011) – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that it has established a new financial reporting segment, called Specialty Diagnostics, following its acquisition of Phadia, a global leader in blood tests for the clinical diagnosis and monitoring of allergies and autoimmune diseases. As a result, Thermo Fisher's financial performance will be reported in three segments instead of two, effective with the company's third fiscal quarter of 2011.

The new Specialty Diagnostics Segment will consist of five businesses: Anatomical Pathology, Clinical Diagnostics, and Microbiology (all formerly part of the Analytical Technologies Segment), ImmunoDiagnostics (formerly Phadia) and the Healthcare Market Channel (formerly part of the Laboratory Products and Services Segment).

Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific, said, "Following our acquisition of Phadia, our Specialty Diagnostics business has significant scale – with more than \$2 billion in revenues – and greater access to a number of high-growth end markets. Our new reporting structure provides investors with better visibility into our company, highlighting not only our leading capabilities in Specialty Diagnostics, but also our high-growth Analytical Technologies and marketing-leading Laboratory Products and Services businesses. It also aligns with the way we manage these businesses to best serve our customers and capitalize on our greatest opportunities for growth."

With this change, Thermo Fisher's three reporting segments will be as follows:

- **Analytical Technologies Segment:** Analytical Instruments and Biosciences
- **Specialty Diagnostics Segment:** Anatomical Pathology, Clinical Diagnostics, Microbiology, ImmunoDiagnostics and Healthcare Market Channel
- **Laboratory Products and Services Segment:** Laboratory Products, Research and Safety Market Channels, and BioPharma Services

The company has included later in this press release certain unaudited historical financial results reflecting the new segment reporting structure. This information is also available in the

reconciliation of GAAP to Non-GAAP financials that can be found in the Investors section of the company's website at [www.thermofisher.com](http://www.thermofisher.com). The segment changes do not impact the company's audited consolidated balance sheet, statement of income or cash flows.

### **Use of Non-GAAP Financial Measures**

In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), we use the non-GAAP financial measure adjusted operating income, which excludes, among other things, restructuring and other costs/income and amortization of acquisition-related intangible assets. We exclude these items because they are outside of our normal operations. We believe that the use of non-GAAP measures helps investors to gain a better understanding of our core operating results and future prospects, consistent with how management measures and forecasts the company's performance, especially when comparing such results to previous periods.

Thermo Fisher's management uses non-GAAP measures, in addition to GAAP financial measures, as the basis for measuring the company's core operating performance and comparing such performance to that of prior periods and to the performance of our competitors. Such measures are also used by management in their financial and operating decision-making and for compensation purposes.

The non-GAAP financial measure of Thermo Fisher's results of operations included in this press release is not meant to be considered superior to or a substitute for Thermo Fisher's results of operations prepared in accordance with GAAP. A reconciliation of the non-GAAP financial measure to the most directly comparable GAAP financial measure is set forth in the accompanying tables.

### **About Thermo Fisher Scientific**

Thermo Fisher Scientific Inc. (NYSE:TMO - News) is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. With revenues of nearly \$11 billion, we have approximately 37,000 employees and serve customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as in environmental and process control industries. We create value for our key stakeholders through two premier brands, Thermo Scientific and Fisher Scientific, which offer a unique combination of continuous technology development and the most convenient purchasing options. Our products and services help accelerate the pace of scientific discovery, and solve analytical challenges ranging from complex research to routine testing to field applications. Visit [www.thermofisher.com](http://www.thermofisher.com).

###

**Consolidated Statement of Income (unaudited) (a)**
**Segment Data**

(In millions)	Three Months Ended				2010
	Apr 3, 2010	Jul 3, 2010	Oct 2, 2010	Dec 31, 2010	
<b>Revenues</b>					
Analytical Technologies	\$ 769.3	\$ 760.8	\$ 827.9	\$ 880.2	\$ 3,238.2
Specialty Diagnostics	555.8	544.5	513.1	535.6	2,149.0
Laboratory Products and Services	1,416.1	1,412.2	1,407.7	1,414.9	5,650.9
Eliminations	(114.3)	(121.8)	(120.0)	(111.8)	(467.9)
Consolidated Revenues	\$ 2,626.9	\$ 2,595.7	\$ 2,628.7	\$ 2,718.9	\$ 10,570.2
<b>Operating Income</b>					
Analytical Technologies	\$ 125.0	\$ 116.8	\$ 143.5	\$ 164.8	\$ 550.1
Specialty Diagnostics	126.4	124.4	118.1	119.0	487.9
Laboratory Products and Services	203.5	206.2	189.5	202.9	802.1
Subtotal Reportable Segments (Adjusted Operating Income)	454.9	447.4	451.1	486.7	1,840.1
Cost of Revenues Charges (b)	(5.1)	(3.7)	(2.5)	(4.7)	(16.0)
Selling, General and Administrative (Costs) Income, Net (c)	(1.1)	0.2	(0.5)	(1.6)	(3.0)
Restructuring and Other Costs, Net (d)	(17.4)	(8.2)	(10.3)	(24.5)	(60.4)
Amortization of Acquisition-related Intangible Assets	(146.7)	(137.8)	(135.1)	(135.1)	(554.7)
GAAP Operating Income (a)	\$ 284.6	\$ 297.9	\$ 302.7	\$ 320.8	\$ 1,206.0
Three Months Ended					
(In millions)	Apr 2, 2011	Jul 2, 2011			Six Months Ended 2011
<b>Revenues</b>					
Analytical Technologies	\$ 830.2	\$ 929.2			\$ 1,759.4
Specialty Diagnostics	576.6	569.5			1,146.1
Laboratory Products and Services	1,442.5	1,528.6			2,971.1
Eliminations	(127.9)	(129.9)			(257.8)
Consolidated Revenues	\$ 2,721.4	\$ 2,897.4			\$ 5,618.8
<b>Operating Income</b>					
Analytical Technologies	\$ 137.0	\$ 159.0			\$ 296.0
Specialty Diagnostics	141.9	135.7			277.6
Laboratory Products and Services	199.3	215.6			414.9
Subtotal Reportable Segments (Adjusted Operating Income)	478.2	510.3			988.5
Cost of Revenues Charges (b)	(2.9)	(15.4)			(18.3)
Selling, General and Administrative (Costs) Income, Net (c)	(3.1)	(38.0)			(41.1)
Restructuring and Other Costs, Net (d)	(15.3)	(39.9)			(55.2)
Amortization of Acquisition-related Intangible Assets	(135.4)	(151.2)			(286.6)
GAAP Operating Income (a)	\$ 321.5	\$ 265.8			\$ 587.3

(a) "GAAP" (reported) results were determined in accordance with U.S. generally accepted accounting principles (GAAP). Results in all periods have been adjusted to omit from continuing operations the results of the discontinued operations of the Athena Diagnostics and Lancaster Laboratories businesses sold on April 4, 2011.

(b) Reported results in 2010 include \$3.6, \$2.4, \$1.4, \$4.0 and \$11.4 for the quarters and full year, respectively, of charges for the sale of inventories revalued at the date of acquisition and \$1.5, \$1.3, \$1.1, \$0.7 and \$4.6 for the quarters and full year, respectively, of accelerated depreciation on manufacturing assets to be abandoned due to facility consolidations. Reported results in 2011 include \$2.0, \$14.6 and \$16.6 for the quarters and first half, respectively, of charges for the sale of inventories revalued at the date of acquisition and \$0.9, \$0.8 and \$1.7 for the quarters and first half, respectively, of accelerated depreciation on manufacturing assets to be abandoned due to facility consolidations.

(c) Reported results include transaction costs related to acquisitions and, in Q4 2010, a \$5.2 charge due to revisions of estimated contingent consideration related to acquisitions and a \$10.9 gain on settlement with product liability insurers.

(d) Reported results include restructuring and other costs, net, consisting principally of severance, abandoned facility and other expenses of headcount reductions within several businesses and real estate consolidations. Reported results in Q1 2010 include a \$6.0 loss on a patent infringement claim that arose at a business unit prior to its acquisition by the company and in Q4 2010, \$17.0 of impairment of intangible assets associated with several small business units. Reported results in Q2 2011 include \$21.6 of cash compensation from monetizing equity awards held by Dionex employees at the date of acquisition.